Peptide record

TPDB01910

Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Toxicity standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB01910
Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Functional / health-promoting peptides
AntiBP3 dbAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 dbACP iACP-DRLF Antifungipept dbAMP 3.0 i2APP AI4AVP DRAMP DRAVP 2.0
standard
No
A 15-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
VGALAVVVWLWLWLW
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C96H135N19O16
RNDCEQHIKMFPSTY
LWV
1811.25
6.02
0
0
14
-0
-3.31
2.107
194.67
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
22000
12.15
0
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
4
L
0
K
0
M
0
F
0
P
0
S
0
T
4
W
0
Y
4
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 4 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 4 Y: 0 V: 4
Chemical Descriptors
15 reviewed residue count
C96H135N19O16 sequence-only estimate (linear, free termini)
1811.25 sequence-only estimate (linear, free termini)
6.02 sequence-only estimate (linear, free termini)
-0 sequence-only estimate (linear, free termini)
-3.31 sequence-only estimate (linear, free termini)
2.107 sequence-only estimate (linear, free termini)
Evidence Records 1 records
Evidence 1 Activity

Source & Reference

dbAMP dbAMP 3.0 DRAMP CancerPPD 2.0 dbACP Antifungipept DRAVP 2.0